Foundation for the National Institute of Health Inc
Public records show a registered, tax-exempt organization in good standing.
What it says it does
TO CREATE AND LEAD ALLIANCES AND PUBLIC-PRIVATE PARTNERSHIPS THAT ADVANCE BREAKTHROUGH BIOMEDICAL DISCOVERIES AND IMPROVE THE QUALITY OF PEOPLE'S LIVES
- Income
- $78.5 million
- Spending
- $76.8 million
- Spent on programs
- 86%
- Reserves
- 5.8 months of spending
- Largest source of income
- donations and private grants, 90%
- Employees
- 122
- Volunteers
- 21
- Highest pay
- $689,835, chief executive officer
Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Financial health
Good: 85 out of 100. Higher than 63% of charities in its peer group (medical research, $10m to $100m).
Reserves
20 of 35Spendable reserves would cover 5.8 months of spending.
Debt
20 of 20It owes 7% of what it owns.
Living within its means
15 of 15Income exceeded spending by 2% of income.
Income trend
15 of 15Income rose 29% on the year before.
Spending floor
15 of 1586% of spending went to programs and raising each dollar of donations cost 0 cents.
Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Governance
Strong: 100 out of 100. Higher than 45% of charities in its peer group (medical research, $10m to $100m).
Independent board
25 of 2521 of 22 voting board members are independent.
Conflict of interest policy
15 of 15Has a written conflict of interest policy.
Whistleblower policy
8 of 8Has a written whistleblower policy.
Record keeping policy
7 of 7Has a written policy on keeping and destroying records.
Board minutes
5 of 5Keeps minutes of board meetings.
Board sees the tax return
10 of 10Gave the board a copy of this return before filing it.
Pay set independently
5 of 5Sets its chief executive's pay through independent review and comparison.
Independent check of accounts
15 of 15Its accounts were audited by an independent accountant.
No reported misuse
10 of 10Reports no diversion of assets, excess benefits or loans to insiders.
Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Impact evidence
Describes programs. Its tax return describes what it does but we have found no measurable results in it.
Programs described in its return (2)
- $64.2 million spent. PROGRAM ONE - RESEARCH PROGRAMS - ACCELERATING MEDICINES PARTNERSHIP PROGRAM The FNIH manages the Accelerating Medicines Partnership (AMP) program with the interests of the collective scientific and medical research communities in mind. Its mission is to improve understanding of disease pathways, facilitate better selection of targets for treatment, and identify platforms and processes to accelerate new and effective therapies to patients. All AMP projects operate under the broad principle of delivering pre-competitive advancements to the research and medical fields and enabling the broadest possible access and use of AMP research discoveries. A critical component of each public-private partnership in the AMP program is an agreement among partners to make data and analyses arising from the collaboration publicly accessible to benefit the broader biomedical community. Individual AMP projects frequently establish public portals to rapidly disseminate data from their research efforts, and AMP-funded publications are required to be made available publicly within specific timeframes. At the center of the AMP program is a common goal of accelerating new and effective therapies to patients. AMP projects work towards this goal by identifying clinically relevant disease targets, improving identification of patients most likely to respond to a particular treatment, and safely reducing the development timelines for life-saving therapies and improvements in patient outcomes. The AMP program celebrated its 10-year anniversary in 2024 with a two-day symposium spotlighting the wide-ranging impact of the initiative. BIOMARKERS CONSORTIUM The Biomarkers Consortium (BC) creates and leads cross-sector efforts that validate and qualify biomarkers and other tools to accelerate better decision making for the development of new therapeutics and health technologies. It convenes government, industry, patients and patient advocacy groups, and not-for-profit organizations to address one of the most pressing needs in the diagnosis and treatment of disease: the development and the seeking of regulatory approval for disease biomarkers and surrogate endpoints. The BC is helping facilitate, catalyze, and support a new era of precision medicine by advancing biomarker science to enable earlier interventions, personalized treatments, and better outcomes in disease prevention, detection, diagnosis, and therapy. GENECONVENE GLOBAL COLLABORATIVE The GeneConvene Global Collaborative continues to advance best practices and support informed decision-making on the scientific, regulatory, and policy questions raised by the development of genetic biocontrol technologies to control the spread of malaria and other mosquito-borne diseases. GeneConvene convened in 2024 a working group of developers preparing for field trials to assess technologies for entomological monitoring and surveillance, hosting a webinar and meeting on environmental monitoring, and leading a Gene Drive Research Forum discussion of the opportunities for ecological modeling to further contribute to safety assessments. Through the African Genetic Biocontrol Consortium, the program also conducted two workshops for scientists and science communicators to build relationships and skills. GeneConvene also strengthened biosafety regulatory capacity through a training conducted with the African Union Development Agency-NEPAD and sponsored a course for 50 faculty and PhD-level scientists from African institutions on genome editing. RESEARCH PROGRAMS FOR ACCELERATING NEW THERAPIES RESEARCHING COVID TO ENHANCE RECOVERY-TREATING LONG COVID (RECOVER-TLC) RECOVER-TLC is a partnership between the NIH's National Institute of Allergy and Infectious Diseases and the FNIH, with the overarching goal to launch additional Long COVID clinical trials with promising agents. Therapeutic submissions were submitted to the online portal in 2024, and a process was created to enable uniform assessment of all submitted agents. These efforts initiated early working group formation, with the Antiviral Working Group conducting initial agent review by the end of 2024. NEW AMP PROJECTS AMP AMYOTROPHIC LATERAL SCLEROSIS (ALS) AMP ALS was launched in 2024 to expedite the identification of biomarkers and clinical outcome assessments that would allow earlier diagnosis and accelerated drug development for ALS, a progressive and ultimately fatal neurological disease. The project will create the largest data source for ALS research. AMP PARKINSON'S DISEASE AND RELATED DISORDERS (PDRD) AMP PDRD, launched in 2024, seeks to employ a data-driven approach to identify and validate biomarkers distinguishing Parkinson's disease from related diseases, with an overarching goal to enhance the success of clinical trials and ultimately broaden treatment options for individuals affected by these conditions. BIOMARKERS CONSORTIUM RESEARCH PROJECTS EARLY DETECTION OF ALZHEIMER'S DISEASE: PLASMA A Results of a Plasma A project study on early diagnosis of Alzheimer's disease were published last year. This head-to-head evaluation and cross-platform validation of biomarkers that most accurately detect amyloid plaques and other Alzheimer's-related pathologies revealed that the performance of some blood plasma tests were as good as cerebrospinal fluid tests. This finding suggested that simple blood tests could replace invasive spinal taps or costly brain scans for many patients. The study confirmed that blood tests are an accessible, less invasive, and highly accurate method of detecting amyloid plaques. The study offered further confirmation that blood tests measuring levels of the protein p-tau217 are the most accurate in determining the presence and amount of amyloid plaques. Alzheimer's blood tests could speed future drug development by helping researchers select the optimal participants for clinical trials. NEUROFILAMENT AS A BLOOD-BASED BIOMARKER OF NEURODEGENERATION IN FAMILIAL FTD The earliest stages of frontotemporal d
- $1.6 million spent. PROGRAM TWO - AWARDS, EVENTS, EDUCATION/TRAINING PROGRAMS - POWERING SCIENCE: 2024 FNIH AWARDS THE LURIE PRIZE IN BIOMEDICAL SCIENCES The Lurie Prize recognized outstanding achievement by promising scientists aged 52 years old or younger. The award included a $100,000 honorarium. PAUL-GALLIN TRAILBLAZER PRIZE FOR PHYSICIAN-SCIENTISTS The Paul-Gallin Trailblazer Prize recognizes the outstanding contributions of early- to mid-career physician-scientists whose research translates basic discoveries into novel approaches for diagnosing, preventing, treating, or curing disease and disability. The award includes a $100,000 honorarium. CHARLES A. SANDERS, MD, PARTNERSHIP AWARD We recognize our partners and their contributions through the annual Charles A. Sanders, MD, Partnership Award. This prize recognizes persons and/or organizations that have made significant contributions to our work in creating, implementing, and nurturing public-private partnerships that build bridges to breakthroughs in improved therapeutics, diagnostics, and potential cures. KOVLER PRIZE FOR TRUST IN LIFE SCIENCE JOURNALISM The Kovler Prize, which debuted in 2024 and carries a $25,000 honorarium, recognizes individual reporters who make complex health- and science-related topics digestible for the public. EVENTS AND EDUCATION In collaboration with the NIH and generous donors and partners, the FNIH manages training initiatives that offer educational opportunities to science students, ranging from high school to post-doctoral scholars, crossing boundaries and cultures. They learn through intensive training, collaborative engagement, mentoring, and hands-on research. Legacy funds from individual benefactors and foundations help move scientific achievement farther, faster, and give hope to future patients. Individual programs provide financial support, mentoring, and recognition to promising young scientists. Here is a just a sample of how the FNIH and its supporters power science: - The Deeda Blair Research Initiative for Disorders of the Brain awarded in 2024 three promising early-career physician-scientists with bold approaches to address mental illness. Each awardee received $200,000. This initiative was established by Mrs. William McCormick Blair, Jr., a member of the FNIH Board of Directors. - The Medical Research Scholars Program is a one-year intensive training program on the NIH campus offering medical, dental, and veterinary students opportunities to become engaged in research early in their careers. The FNIH has supported a total of 572 scholars since the program was established. - The FNIH promotes emerging research from up-and-coming scientists through annual lectures co-sponsored by the National Eye Institute, the National Institute of Neurological Disorders and Stroke, the National Institute of Allergy and Infectious Diseases, the National Center for Complementary and Integrative Health, and elsewhere. - For a complete list of all the ways the FNIH is powering science, go to the FNIH website.
Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Legitimacy checks
Is it registered with the IRS? Passed.
Listed in the IRS master file of tax-exempt organizations as a 501(c)(3) charitable organization.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.
Has the IRS revoked its tax-exempt status? Passed.
Not on the IRS automatic revocation list.
Source: Automatic revocation of exemption list, Internal Revenue Service, file dated November 6, 2026.
Are donations tax-deductible? Passed.
On the IRS list of organizations eligible to receive tax-deductible contributions.
Source: Publication 78 data: organizations eligible for tax-deductible contributions, Internal Revenue Service, file dated October 13, 2026.
Is it keeping up with its IRS filings? Passed.
Most recent return on file covers the year ending December 2024.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.
How long has it been tax-exempt? Passed.
Recognized by the IRS since April 1997.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.
Is it in good standing with state regulators? Passed.
Not on California's list of charities barred from soliciting. Other states are not yet checked.
Source: May Not Operate or Solicit for Charitable Purposes list, California Attorney General, Registry of Charities and Fundraisers, file dated November 4, 2026.
Ratings and checks are our reading of public records, using the published method. They are not a statement about anyone's honesty. If you work for this organization, you can send corrections or results, confirm you want gifts through Veridonate, or ask to be removed from giving.